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Low-Flow Aortic Stenosis*Patrick T. O’Gara, MDSEE PAGE 588C ollective appreciation of low-ﬂow, low-gradient (LF-LG) aortic stenosis (AS) hasincreased signiﬁcantly in recent times. Clin-
ical practice guidelines (1,2) provide concordant
recommendations for the evaluation and treatment
of patients with LF-LG AS with either low left
ventricular (LV) ejection fraction (EF) or normal
LV EF. Patients with LF-LG AS constitute an in-
creasing percentage of patients currently seen in
multidisciplinary heart valve centers, and they pose
challenging management issues that relate to the ac-
curacy of the assessment of ﬂow, AS severity, and
LV function. Observational studies have consistently
reported reduced survival for patients with low-
compared with normal-ﬂow AS and for patients with
low-ﬂow AS managed conservatively compared with
those receiving aortic valve replacement (AVR) (3,4).
Transcatheter aortic valve replacement (TAVR) is
often preferred over surgical AVR for such patients,
but the decision-making process is complex and
must be individualized. Because survival and func-
tional outcomes for patients with low-ﬂow AS are
compromised, improved methods of risk stratiﬁca-
tion are needed to target therapies more effectively.
In this issue of JACC: Cardiovascular Interventions,
Dahou et al. (5) add to the many observations their
group has made regarding the presentation, natural*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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Cardiovascular Interventions or the American College of Cardiology.
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to disclose.history, evaluation, management, and outcomes of
patients with severe LF-LG AS. Among 211 patients
with severe LF-LG AS and low EF prospectively
enrolled in the TOPAS (True or Pseudo-severe Aortic
Stenosis) study, the presence of more than mild,
functional tricuspid regurgitation (TR) was indepen-
dently associated with all-cause and cardiovascular
mortality over a mean follow-up of 2.4 years.
Increasing degrees of TR were associated with higher
mortality risk, even after multivariable adjustment.Patientswithmore thanmoderate TRhad lower 30-day
survival following AVR than those with lesser degrees
of TR. Whether more than mild TR should be routinely
addressed at the time of surgical AVR in such high-risk
patients cannot be answered by this study. Surgical
practice has already moved aggressively toward
tricuspid valve repair at the time of left-sided valve
surgery for mild or greater degrees of TR, particularly
in the setting of tricuspid annular dilation (>40 mm)
(1,2,6,7). Transcatheter treatment of functional TR at
the time of TAVR is not currently available. Alterna-
tively, whether moderate or greater degrees of TR
should be considered a relative contraindication to
aortic valve intervention deserves further scrutiny and
debate. It seems doubtful that patients would be
excluded from AVR on this basis alone. Randomized
controlled trials to answer these questions, however,
would be signiﬁcantly challenged by a lack of equi-
poise among both surgeons and cardiologists.
It is not intuitively obvious how functional TR
independently contributes to the excess mortality
risk observed in patients with severe LF-LG AS and
low EF. As the authors note (5), their study was
limited by the relatively small number of patients, the
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598confounding effects of unmeasured variables, the
difﬁculties inherent in assessing TR severity, and the
lack of more precise, quantitative information
regarding right ventricular function. A single-center
study of 518 TAVR patients reported a 15% preva-
lence of moderate or severe TR (8). The fate of TR
following TAVR was extremely variable and could not
be predicted beforehand. Signiﬁcant TR was signiﬁ-
cantly associated with 2-year mortality only in a
subgroup of patients with EF >0.40. Hutter et al. (9)
reported that $ moderate TR was not an indepen-
dent predictor of 1-year all-cause mortality among 29
TAVR patients. In contrast, among 553 patients in the
inoperable cohort of the PARTNER (Placement of
Aortic Transcatheter Valves) II trial, moderate/severe
TR was signiﬁcantly associated with 1-year all-cause
mortality, whereas qualitatively-assessed right
ventricular dysfunction was not (10). The effect of TR
on survival was not assessed in a PARTNER trial
analysis of the predictors of mortality and outcome in
530 inoperable or high-risk patients with low-ﬂow
severe AS (4).
The adverse effects of TR on long-term outcomes
have been reported for other patient cohorts. In a
study of 5,223 Veterans Affairs patients followed
over 4 years, increasing TR severity was indepen-
dently associated with worse survival (11). The
presence of any degree of TR was independently
associated with reduced long-term survival among
117 patients with ischemic or dilated cardiomy-
opathy referred for transplant evaluation (12).
Similarly, severe TR was identiﬁed as an indepen-
dent predictor of mortality among 1,421 patients
with LV EF #0.35 (13). A subgroup analysis from
a study of 576 heart failure patients showed
that moderate or severe TR was linked to worse
survival among patients with mild or moderateLV systolic dysfunction, but not for patients with
severely depressed LV systolic function or with
elevated amino-terminal brain natriuretic peptide
levels (14).
It is now more apparent that functional TR is
not as innocuous as previously assumed. Further
study is clearly needed to unravel the mechanism(s)
by which TR worsens survival and to verify the
preliminary observations made in these several,
methodologically-limited studies regarding its in-
dependent contribution to outcomes in various
patient cohorts. Our surgical colleagues have been
aware for many years of the adverse long-term
consequences of not addressing functional TR at
the time of left-sided valve surgery, related in part
to the high morbidity and mortality risks associated
with reoperative tricuspid valve surgery. It may be
fair to say that the tricuspid valve is no longer
the “forgotten valve.” Accurate and quantitative
assessment of its function, as well as that of the
supporting right ventricle, with whose fate it is
intertwined, remains a challenge that may com-
plicate the design and execution of interventional
trials with hard clinical endpoints. Dahou et al. (5)
rightfully question whether functional TR is a risk
marker or risk factor for mortality in patients with
LF-LG AS and low EF. The same question could be
posed for patients with other types of heart disease
and functional TR. It is hoped that this resurgent
respect for TR will spur additional investigations to
help establish best practices for risk assessment
and treatment.
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